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BACKGROUND AND PURPOSE
Adenophostin A (AdA) is a potent agonist of inositol 1,4,5-trisphosphate receptors (IP3R). AdA shares with IP3 the essential
features of all IP3R agonists, namely structures equivalent to the 4,5-bisphosphate and 6-hydroxyl of IP3, but the basis of its
increased afﬁnity is unclear. Hitherto, the 2′-phosphate of AdA has been thought to provide a supra-optimal mimic of the
1-phosphate of IP3.
EXPERIMENTAL APPROACH
We examined the structural determinants of AdA binding to type 1 IP3R (IP3R1). Chemical synthesis and mutational analysis of
IP3R1 were combined with 3H-IP3 binding to full-length IP3R1 and its N-terminal fragments, and Ca2+ release assays from
recombinant IP3R1 expressed in DT40 cells.
KEY RESULTS
Adenophostin A is at least 12-fold more potent than IP3 in functional assays, and the IP3-binding core (IBC, residues 224–604
of IP3R1) is sufﬁcient for this high-afﬁnity binding of AdA. Removal of the 2′-phosphate from AdA (to give 2′-dephospho-AdA)
had signiﬁcantly lesser effects on its afﬁnity for the IBC than did removal of the 1-phosphate from IP3 (to give inositol
4,5-bisphosphate). Mutation of the only residue (R568) that interacts directly with the 1-phosphate of IP3 decreased similarly
(by ~30-fold) the afﬁnity for IP3 and AdA, but mutating R504, which has been proposed to form a cation-p interaction with
the adenine of AdA, more profoundly reduced the afﬁnity of IP3R for AdA (353-fold) than for IP3 (13-fold).
CONCLUSIONS AND IMPLICATIONS
The 2′-phosphate of AdA is not a major determinant of its high afﬁnity. R504 in the receptor, most likely via a cation-p
interaction, contributes speciﬁcally to AdA binding.
Abbreviations
AdA, adenophostin A; CLM, cytosol-like medium; IBC, IP3-binding core; IP2, inositol 4,5-bisphosphate; IP3, inositol
1,4,5-trisphosphate; IP3R, IP3 receptor; Kd, equilibrium dissociation constant; nHill, Hill coefﬁcient; NT, N-terminal; TEM,
Tris/EDTA medium
Introduction
Receptors for inositol 1,4,5-trisphosphate (IP3R,
nomenclature follows Alexander et al., 2009) are
intracellular Ca
2+ channels. They are expressed in
the membranes of the endoplasmic reticulum of
most animal cells (Foskett et al., 2007) and they
both initiate and propagate the Ca
2+ signals evoked
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et al., 2003). In vertebrates, three genes encode
closely related subtypes of the IP3R, which assemble
into both homo- and hetero-tetrameric channels
(Taylor et al., 1999). The different subtypes share
many features (Foskett et al., 2007). Each subunit
has a single IP3-binding site towards the N-terminal,
a large cytosolic regulatory domain, and six trans-
membrane domains, the last pair of which from
each subunit, together with the intervening luminal
loop, form the pore (Ramos-Franco et al., 1999;
Taylor et al., 2004). For all IP3R, IP3 binding initiates
the conformational changes that lead to opening of
the channel. The IP3-binding core [IBC, residues
224–604 of type 1 IP3R (IP3R1)] is entirely respon-
sible for this initial recognition. The two domains (a
and b) of the IBC form a clam-like structure lined
with the basic residues that coordinate the phos-
phate groups of IP3 (Bosanac et al., 2002)
(Figure 1A). The 4,5-bisphosphate and 6-hydroxyl
groups of IP3 are important for binding to IP3R
(Potter and Lampe, 1995), and each forms extensive
interactions with the IBC. The 4-phosphate forms
hydrogen bonds with several residues in the
Figure 1
Structures of the IBC and the ligands used. Structure of the IBC (PDB 1N4K) with the enlarged panel highlighting the residues (R504, R568
and K569) mutated in this study and their interactions with the phosphate groups of IP3. The red spheres represent water (A). Structures of the
ligands used highlighting the 1-phosphate of IP3 and 2′-phosphate of AdA (B). AdA, adenophostin A; IBC, IP3-binding core; IP3, inositol
1,4,5-trisphosphate.
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residues predominantly within the a-domain and
the 6-hydroxyl interacts indirectly via water with
the backbone of K569 (Figure 1A). The 1-phosphate
of IP3 is not essential for binding to IP3R, but it
substantially increases the afﬁnity of IP3 (Nerou
et al., 2001); it interacts directly only with R568 and
indirectly via a water molecule with the backbone of
K569 (Bosanac et al., 2002) (Figure 1A).
Adenophostins (Figure 1B) were originally iso-
lated from Penicillium brevicompactum (Takahashi
et al., 1994a,b,c). They are potent agonists of IP3R
(Takahashi et al., 1994b,c; Hirota et al., 1995; March-
ant et al., 1997a; Shuto et al., 1998; Correa et al.,
2001); they are not metabolized by the enzymes that
degrade IP3 and their structures are based on a
glucose, rather than a myo-inositol, ring (Figure 1B).
Adenophostin A (AdA) has proven a useful tool with
which to explore the properties of IP3R (Hirota et al.,
1995; Dellis et al., 2006; Marchant and Parker, 1998;
Yoshida et al., 1998; Parekh et al., 2002), and it has
generated considerable interest in the synthesis of
novelAdAanalogues(Shutoet al.,1998;Correaet al.,
2001; Borissow et al., 2005; Mochizuki et al., 2006).
Inositol 1,4,5-trisphosphate and AdA are each
full agonists of the IP3R (Rossi et al., 2009). Both IP3
and AdA bind to the IBC, and despite their struc-
tural differences, the 3″,4″-bisphosphate and
2″-hydroxyl groups of AdA evidently mimic the
essential 4,5-bisphosphate and 6-hydroxyl of IP3
(Figure 1B) (Takahashi et al., 1994c; Hotoda et al.,
1999; Correa et al., 2001; Rosenberg et al., 2003).
These features probably account for the binding of
AdA to the IBC (Rosenberg et al., 2003), but they do
not explain the ability of AdA to bind to IP3R with
greater afﬁnity than IP3. Hitherto, a favoured sug-
gestion is that the 2′-phosphate of AdA, which is
thought to mimic the 1-phosphate of IP3
(Figure 1B), is ‘supra-optimally’ positioned and
thereby interacts more strongly with R568 and K569
than does the 1-phosphate of IP3 (Takahashi et al.,
1994c; Wilcox et al., 1995; Hotoda et al., 1999).
Alternatively, the adenine of AdA may interact
directly with the IP3R (Hotoda et al., 1999;
Glouchankova et al., 2000; Rosenberg et al., 2003).
Such an interaction would need to be rather tolerant
of changes to the adenine group because even sub-
stantial modiﬁcations to it cause only modest
decreases in afﬁnity (Correa et al., 2001; Sureshan
et al., 2008). Deﬁning the mechanisms responsible
for high-afﬁnity binding of AdA would both provide
an important step towards rational development of
ligands of the IP3R with increased afﬁnity, and con-
tribute to resolving the mechanisms whereby IP3
and AdA can have different effects on Ca
2+ signalling
(Rossi et al., 2010). Here, we have used synthetic
analogues of IP3 and AdA and systematic mutagen-
esis of the IBC to address the structural basis of the
high-afﬁnity binding of AdA to IP3R.
Methods
Stable expression of mutant IP3R1 in
DT40 cells
Cloning of rat IP3R1 (without the S1 splice site) into
the pENTR1A vector has been reported previously
(Rossi et al., 2009). The QuikChange II XL site-
directed mutagenesis kit (Stratagene, La Jolla, CA,
USA) was used to introduce point mutations
into rat IP3R1 using the primers (5′-3′) forward: TCA
CAGCAAGACTACCAGAAGAACCAGGAGTAC, and
reverse: GTACTCCTGGTTCTTCTGGTAGTCTTGCT
GTGA for R568Q, and forward: TTCTCTAAGCCCAA
CCAAGAGCGGCAGAAGCTG, and reverse: CAG
CTTCTGCCGCTCTTGGTTGGGCTTAGAGAA for
R504Q. The sequences of all mutant constructs were
conﬁrmed by sequencing of the full-length IP3R.
Mutated IP3R were subcloned into the expression
vector, pcDNA3.2/V5-DEST, by recombination
(Invitrogen, Paisley, UK). DT40 cells stably express-
ing IP3R1 and its mutants were generated by trans-
fection of cells lacking endogenous IP3R (Sugawara
et al., 1997). DT40 cells were cultured in RPMI 1640
medium supplemented with fetal bovine serum
(10%), heat-inactivated chicken serum (1%),
2-mercaptoethanol (50 mM) and glutamine (2 mM).
Cells were grown in suspension at 37°C in an atmo-
sphere of 95% air and 5% CO2, and passaged or used
for Ca
2+ experiments when they reached a density of
~2 ¥ 10
6 cells·mL
-1 (Tovey et al., 2006). IP3R expres-
sion was quantiﬁed by immunoblotting using an
antiserum (Ab1.5) to a peptide corresponding to
residues 2733–2749 of rat IP3R1.
Mutagenesis of N-terminal fragments
of IP3R1
N-terminal fragments of IP3R1 (IBC, residues 224–
604; NT, residues 1–604) were ampliﬁed by PCR
from the rat IP3R1 clone lacking the S1 splice
site and ligated into pTrcHisA vectors for expres-
sion of N-terminally tagged His6 fusion proteins
as previously described (Rossi et al., 2009). The IBC
included the S1 splice site, but the NT lacked
it. The presence of the S1 splice site does not
affect the equilibrium dissociation constant (Kd)
of the IBC for IP3 (data not shown). All fragments
are numbered by reference to the full-length
(S1
+) rat IP3R1 (GenBank accession number:
GQ233032.1). The QuikChange II XL site-directed
mutagenesis kit was used to introduce point muta-
tions into the IBC and NT constructs in pTrcHisA
BJP
AM Rossi et al.
1072 British Journal of Pharmacology (2010) 161 1070–1085vectors using the primers listed in the preceding
section. The sequences of all constructs were
conﬁrmed.
Expression of fragments of IP3R1
His6-tagged IBC and NT fragments were expressed
as described previously (Rossi et al., 2009). Brieﬂy,
constructs were transformed into E. coli strain
BL21(DE3). Cells were grown in Luria-Bertani
medium containing ampicillin (100 mg·mL
-1)a t
22°C until the OD600 reached 1.0–1.5. The culture
was then induced by addition of isopropyl b-D-
thiogalactoside (0.5 mM), and after 20 h at 15°C,
cells were harvested and lysates were prepared in
Tris/EDTA medium (TEM: 50 mM Tris, 1 mM EDTA,
pH 8.3) as described (Rossi et al., 2009). Expression
was detected by immunoblotting using an anti-His6
antibody (Sigma, Poole, Dorset, UK). Proteins were
cleaved from the His6 tags by incubating bacterial
lysate (6 h, 4°C) with thrombin (43 units·mg
-1 bac-
terial protein) in phosphate-buffered saline. Cleav-
age was monitored by immunoblotting (Rossi et al.,
2009) using anti-His6 antibody and antisera raised to
peptides corresponding to residues 62–75 (Ab1)
(Cardy et al., 1997) or 326–343 (the SI splice site,
Ab1.1) of IP3R1 (Rossi et al., 2009) for the NT and
IBC respectively.
Puriﬁcation of IP3R from rat cerebellum
All animal care and experimental procedures com-
plied with UK Home Ofﬁce policy and with local
animal regulations. Adult male Wistar rats were
humanelykilledbycervicaldislocationandcerebella
were removed, rapidly frozen in liquid nitrogen and
stored at -80°C. IP3R1 was puriﬁed from cerebella
using heparin-afﬁnity chromatography following a
published protocol (Jiang et al., 2002) with some
modiﬁcations (Rossi et al., 2009). Brieﬂy, cerebella
(2 g)werehomogenizedinhomogenizationmedium
[30 mL, HM: 1 M NaCl, 1 mM EDTA, 50 mM Tris,
1 mM benzamidine, Roche protease inhibitor
cocktail (1 tablet per 25 mL), pH 8.3], and then
centrifuged (100 000¥ g, 30 min). The pellet was
solubilized in 20 mL of HM without NaCl, but
supplemented with CHAPS (1.2%). After centrifuga-
tion (100 000¥ g, 1 h), the NaCl concentration of the
supernatantwasincreasedto250 mM,andthesuper-
natant was loaded onto heparin-agarose beads
(5 mL). After 30 min, the beads were washed twice
in glycerol-containing medium [250 mM NaCl,
50 mMTris,10%glycerol,1 mM2-mercaptoethanol,
1 mM benzamidine, 1 mM EGTA, 1% CHAPS, Roche
protease inhibitor cocktail (1 tablet per 50 mL),
pH 8.0]. IP3R were eluted with elution medium
(500 mM NaCl, 50 mM Tris, 10% glycerol, 1 mM
2-mercaptoethanol, 1 mM benzamidine, 1 mM
EGTA, 50 mM Tris, 1% CHAPS, pH 8.0). Samples
(~100 mg protein per mL) were frozen in liquid nitro-
gen and stored at -80°C.
3H-IP3 binding
Equilibrium-competition binding assays were per-
formed as described (Rossi et al., 2009). Brieﬂy,
incubations (500 mL) at 4°C were in either TEM or
cytosol-like medium [CLM: 20 mM NaCl, 140 mM
KCl, 1 mM EGTA, 20 mM PIPES, 2 mM MgCl2,
375 mM CaCl2 (free [Ca
2+] = 220 nM), pH 7.0] con-
taining
3H-IP3 (0.75–3 nM), bacterial lysate (~1–
10 mg protein) or puriﬁed IP3R1 (~2.5 mg), and
competing ligands. For assays using full-length puri-
ﬁed IP3R, all media also included CHAPS (1%). Reac-
tions were terminated after 5 min by addition of
poly(ethylene glycol) 8000 (500 mL, 30%, w/v) and
g-globulin (30 mL, 25 mg·mL
-1), followed by cen-
trifugation (20 000¥ g, 5 min). Radioactivity was
determined by liquid scintillation counting. Non-
speciﬁc binding, determined by addition of 10 mM
IP3, or by extrapolation of competition curves to
inﬁnite IP3 concentration, was <10% of total
binding.
Ca
2+ release by IP3R
A low-afﬁnity Ca
2+ indicator (Mag-ﬂuo-4) was used
to monitor the free [Ca
2+] within the intracellular
Ca
2+ stores of DT40 cells (Laude et al., 2005; Tovey
et al., 2006). DT40 cells stably expressing IP3R1 or
its mutants were centrifuged (650¥ g, 2 min) and
suspended in medium containing 135 mM NaCl,
5.9 mM KCl, 11.6 mM HEPES, 1.5 mM CaCl2,
11.5 mM glucose, 1.2 mM MgCl2, pH 7.3, 1 mg·mL
-1
BSA, 0.4 mg·mL
-1 Pluronic F127 and 20 mM Mag-
ﬂuo-4 AM. After 1 h at 20°C, cells were suspended in
Ca
2+-free CLM supplemented with saponin
(10 mg·mL
-1) to allow selective permeabilization of
the plasma membrane. Permeabilized cells were cen-
trifuged (650¥ g, 2 min), re-suspended in CLM
without Mg
2+, but supplemented with 10 mM carbo-
nyl cyanide p-triﬂuoromethoxyphenylhydrazone
(FCCP) to inhibit mitochondria, and 375 mM CaCl2
to give a ﬁnal free [Ca
2+]o f~220 nM after addition
of 1.5 mM MgATP. Cells (~5 ¥ 10
5 cells per well) were
attached to poly-L-lysine-coated, 96-well, black-
walled plates (Greiner, Stonehouse, UK). Fluores-
cence was recorded at 20°C using a FlexStation III
plate reader (MDS Analytical Technologies, Woking,
Berks, UK) with excitation and emission wave-
lengths of 485 nm and 520 nm respectively. MgATP
(1.5 mM) was added to initiate Ca
2+ uptake, and
when the endoplasmic reticulum had loaded to
steady state with Ca
2+,I P 3, AdA or their analogues
were added. Ca
2+ release is expressed as a fraction of
the ATP-dependent uptake (Tovey et al., 2006).
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Equilibrium binding results and concentration–
effect relationships were ﬁtted to Hill equations
(GraphPad Prism, version 5) from which the Hill
coefﬁcients (nHill), –logIC50 (pIC50) and –logEC50
(pEC50) values were obtained. For equilibrium-
competition binding assays, pKd values were calcu-
lated using the Cheng and Prusoff equation (Cheng
and Prusoff, 1973). Because pEC50 and pKd values are
normally distributed, these results are presented as
means  SEM from n independent experiments. For
comparisons of the ratios between mean values
(EC50 or Kd), statistical analyses compared the differ-
ences between their log values (DpEC50 or DpKd)
(Colquhoun, 1971) with the SEM calculated as
follows, assuming that the population variances
are the same (conﬁrmed using an F-test) (Ott and
Longnecker, 2010):
SEM s
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s
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−−
11
2
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2
12
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2
where, s1 and s2 are the sample standard deviations,
and n1 and n2 are the sample sizes.
Although all analyses were performed using log
values, for greater clarity we present some ratios as
the antilogs of the means  SEM.
Statistical analysis used ANOVA followed by Bon-
ferroni test for selected pairs, or unpaired Student’s
t-tests (GraphPad Prism, version 5). P < 0.05 was
considered signiﬁcant.
Materials
Protease inhibitor cocktail was from Roche
(Burgess Hill, Sussex, UK). Heparin-agarose beads
and sera were from Sigma (Poole, Dorset, UK).
Thrombin was from GE Healthcare (Little Chal-
font, Bucks, UK). CHAPS (3-[3-(cholamidopropyl)
dimethylammonio]-1-propane-sulphonate) was
from Helford Laboratories (Suffolk, UK). RPMI 1640
medium, Pluronic F127 and Mag-ﬂuo-4 AM were
from Invitrogen (Paisley, Scotland).
3H-IP3 (681
GBq·mmol
-1) was from PerkinElmer (Bucks, UK). IP3
was from Alexis Biochemicals (Nottingham, UK).
AdA (Borissow et al., 2005), 2′-dephospho-AdA
(Sureshan et al., 2009), furanophostin (Marwood
et al., 1999) and ribophostin (Jenkins et al., 1997)
were synthesized as previously described. Inositol
4,5-bisphosphate (IP2) was synthesized by hydro-
genolytic deprotection of 1D-2,3,6-tri-O-benzyl-4,5-
bis(dibenzyloxyphosphoryl) myo-inositol (Desai
et al., 1994). All ligands were puriﬁed by ion-
exchange chromatography, fully characterized by
the usual spectroscopic methods and accurately
quantiﬁed by total phosphate assay. The structures
of the ligands used are shown in Figure 1B. Sources
of other reagents either are speciﬁed elsewhere in
the methods or were previously reported (Rossi
et al., 2009).
Results
Stimulation of IP3R1 by AdA
We used full-length IP3R1 puriﬁed from rat cerebel-
lum for binding assays, and DT40 cells expressing
only recombinant IP3R1 to measure Ca
2+ release
from intracellular stores. Most published analyses of
3H-IP3 binding use media similar to TEM because its
high pH and/or low ionic strength reduce the Kd of
IP3R for IP3, thereby increasing the speciﬁc binding
determined with low concentrations of
3H-IP3.A t
the densities that recombinant full-length IP3R are
expressed, it is impracticable to measure
3H-IP3
binding in CLM, although it is feasible with the
bacterially expressed fragments of IP3R. To allow
comparison with published work (Hirota et al.,
1995; Hotoda et al., 1999; Glouchankova et al.,
2000; Rossi et al., 2009) and to provide a direct com-
parison with our analyses of binding to IP3R frag-
ments, we ﬁrst examined IP3 and AdA binding to
IP3R1 in TEM.
In both binding (in TEM) and functional analy-
ses (in CLM), AdA was ~12- to 19-fold more potent
than IP3 (DpKd = 1.27  0.09 and DpEC50 1.09 
0.05) (Figure 2A and B, Table 1, Table S1). These
results are consistent with many previous studies
(Hirota et al., 1995; Shuto et al., 1998; Correa et al.,
2001; Morris et al., 2002). We note, however, that in
one series of studies (Takahashi et al., 1994a,b,c), the
Kd values for IP3 and AdA were incorrectly calculated
from the IC50. The correct Kd for IP3 and AdA calcu-
lated from the data provided are 13 nM and
0.73 nM, respectively, suggesting that in these
studies too, AdA bound with about 18-fold greater
afﬁnity than IP3, rather than the stated 100-fold
difference.
Inositol 1,4,5-trisphosphate binding is entirely
mediatedbyresiduesintheIBC(Bosanacet al.,2002)
(Figure 1A). We therefore compared IP3 and AdA
binding to the isolated NT, initially in TEM. The
results, consistent with a previous analysis of a
slightly shorter NT fragment of IP3R1 (residues
1–580) (Glouchankova et al., 2000), establish that
the NT alone binds AdA with about 15-fold greater
afﬁnity (DpKd = 1.18  0.12) than IP3 (Figure 2C,
Table 2 and Table S1). To allow more direct
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IP3 and AdA binding to the isolated IBC and NT in
CLM. These results conﬁrm the expected substantial
decrease in afﬁnity for IP3 in CLM (~20-fold relative
to TEM). More importantly, they establish that in
CLM the relative afﬁnities for AdA and IP3 are not
signiﬁcantly different for the IBC and NT (DpKd =
1.37  0.07 for the IBC, and 1.14  0.21 for the NT)
Figure 2
Interactions of AdA, IP3, and their dephospho analogues with IP3R and its N-terminal (NT) fragments. Equilibrium-competition binding to puriﬁed
IP3R1 using
3H-IP3 (1.5 nM) and the indicated ligands in TEM (A). Ca
2+ release from permeabilized DT40-IP3R1 cells evoked by the indicated ligands
(B). Equilibrium-competition binding to the NT using
3H-IP3 (1.5 nM) and the indicated ligands in TEM (C). Equilibrium-competition binding to
the IBC using 3H-IP3 (0.75 nM) and the indicated ligands in CLM (D). Equilibrium-competition binding to the NT using 3H-IP3 (1.5 nM) and the
indicated ligands in CLM (E). The key to the symbols shown in panel A applies to all ﬁve panels (A–E). For each analysis (A–E) the Kd (from binding)
or EC50 (from functional assays) is shown as a ratio for IP3 versus AdA (F). For each analysis (A–E), the Kd or EC50 is shown as a ratio for the
dephospho analogue relative to IP3 or AdA (G). Results are means  SEM, n  4. DT40-IP3R1 cells, DT40 cells stably expressing rat type 1 IP3R.
AdA, adenophostin A; CLM, cytosol-like medium; IP3, inositol 1,4,5-trisphosphate; IP3R, IP3 receptor; Kd, equilibrium dissociation constant; TEM,
Tris/EDTA medium.
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our assays, the relative afﬁnities of IP3 and AdA for
binding to the full-length receptor and its fragments,
and their relative potencies in functional assays are
not signiﬁcantly different (Figure 2F, Table S1). It is
noteworthy that the nHill for the interactions of AdA
with IP3R consistently tend to be greater than unity
(see Tables 1–4), even when the interactions are with
monomeric IBC or NT (Tables 2 and 3). We and
others have reported similar observations previously
(reviewed in Rossi et al., 2010), although the under-
lying mechanism is unresolved.
These results, which establish that the IBC
includesthestructuraldeterminantsforhigh-afﬁnity
binding of AdA, provide our justiﬁcation for using
the IBC in subsequent experiments to explore the
structural determinants of AdA binding. With the
exception of Gly-268, the residues within the IBC
that coordinate IP3 are conserved between all three
IP3Rsubtypes(Bosanacet al.,2002),andtheIBCfrom
each subtype binds IP3 with the same afﬁnity (Iwai
et al., 2006). This, together with evidence that AdA is
more potent than IP3 in cells that predominantly
express each IP3 receptor subtype (Rossi et al., 2010),
suggests that the results obtained from our subse-
quent analysis of IP3R1 and the IBC from IP3R1 are
probably applicable also to IP3R2 and IP3R3.
The 2-phosphate is not responsible for
high-afﬁnity binding of AdA
The suggestion that the 2′-phosphate of AdA pro-
vides a supra-optimal mimic of the 1-phosphate of
IP3 (Takahashi et al., 1994c; Wilcox et al., 1995;
Hotoda et al., 1999) predicts that removal of each
phosphate moiety should more profoundly reduce
the afﬁnity of AdA for IP3R relative to IP3. We tested
this prediction using synthetic IP2 and
2′-dephospho-AdA (Figure 1B). In equilibrium-
competition binding analyses with full-length IP3R1
(in TEM), IP2 bound with 282-fold lower afﬁnity
than IP3 (DpKd = 2.45  0.10), whereas loss of the
2′-phosphate from AdA caused only a 41-fold
decrease in afﬁnity (DpKd = 1.61  0.11) (Figure 2A,
Table 1 and Table S1). For the IBC in CLM, removal
of the critical phosphate also more substantially
reduced the afﬁnity for IP3 relative to AdA: IP3
bound with 60-fold higher afﬁnity than IP2 (DpKd =
1.78  0.08), whereas the afﬁnities of 2′-dephospho-
AdA and AdA differed by only 29-fold (DpKd = 1.46
 0.12) (Figure 2D, Table 3 and Table S1). Similar
results were obtained with the NT in TEM and CLM
(Figure 2C and E, Tables 2 and 3 and Table S1). In
Ca
2+ release assays, and consistent with the binding
analyses, removal of the 1-phosphate from IP3 more
substantially reduced its potency than did removal
Table 1
Responses of IP3R1 to IP3, AdA and their analogues
Ca
2+ release Binding
EC50 (nM)
Release (%)
Kd (nM)
(pEC50  SEM) (pKd  SEM)
nHill  SEM nHill  SEM
IP3 38.0 79  38 . 5
(7.42  0.02) (8.07  0.03)
1.1  0.2 1.0  0.1
IP2 5012 73  7 2394
(5.30  0.08) (5.62  0.08)
1.4  0.2 0.8  0.1
AdA 3.1 78  3 0.46
(8.51  0.05) (9.34  0.07)
1.4  0.1 1.5  0.1
2’-dephospho-AdA 160 72  3 18.5
(6.80  0.02) (7.73  0.09)
1.3  0.2 0.7  0.1
From experiments similar to those shown in Figure 2A and B, the effects of each analogue on Ca
2+ release from the intracellular stores of
permeabilized DT40-IP3R1 cells and on
3H-IP3 binding to full-length IP3R1 (in TEM) are summarized. Mean EC50 and Kd values are shown
together with means  SEM for pEC50,p K d, Hill coefﬁcients (nHill) and the percentage Ca
2+ release. Results are from at least four independent
experiments, with each Ca2+ release assay performed with three determinations.
AdA, adenophostin A; DT40-IP3R1 cells, DT40 cells stably expressing rat type 1 IP3R; IP2, inositol 4,5-bisphosphate; IP3, inositol 1,4,5-
trisphosphate; IP3R, IP3 receptor; Kd, equilibrium dissociation constant; nHill, Hill coefﬁcient; TEM, Tris/EDTA medium.
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and Table S1). A previous study suggested that loss
of the 2′-phosphate of AdA more profoundly
affected the Kd (Takahashi et al., 1994a). However, as
stated above, the authors miscalculated the Kd from
the IC50, and it is impossible from the data presented
to estimate the correct Kd for 2′-dephospho-AdA. We
note, although it is unclear whether it contributes to
their reported low afﬁnity of 2′-dephospho-AdA for
IP3R, that these authors used 2′-dephospho-AdA
produced enzymatically rather than by synthesis
(Takahashi et al., 1994a).
It is noteworthy that the disparity between the
afﬁnities of IP3 and AdA and their dephospho ana-
logues was exaggerated in TEM (Figure 2G). We have
not further explored the more pronounced effect
of TEM on binding of AdA and IP3 relative to
2′-dephospho-AdA and IP2 (Table 2). The high pH of
TEM favours substantial deprotonation of the phos-
phate groups in all the ligands (Felemez et al., 1999),
perhaps thereby enhancing their binding to the IBC.
The larger effect of TEM on binding of the trispho-
sphate ligands (IP3 and AdA) may reﬂect a greater
effect of the different media (pH, ionic strength,
counter-ions) on the ionization states of these
ligands relative to the bisphosphate ligands. The
results do, however, highlight the necessity to
examine ligand binding to IP3R in medium resem-
bling that used for functional analyses (e.g. CLM) if
the functional and binding analyses are to be com-
pared reliably.
Our demonstration that removal of the
1-phosphate from IP3 reduces both afﬁnity and
potency signiﬁcantly more than does removal of the
2′-phosphate from AdA (Figure 2G) is inconsistent
with the notion that the high afﬁnity of AdA results
from its 2′-phosphate providing a supra-optimal
mimic of the 1-phosphate of IP3 (Takahashi et al.,
1994c).
Contributions of R568 to AdA and
IP3 binding
R568 within the a-domain of the IBC is the only
residue to interact directly with the 1-phosphate of
Table 2
Binding of IP3, AdA and their analogues to the NT fragment of IP3R1 and its mutants assayed in TEM
Kd (nM)
(pKd  SEM)
nHill  SEM
NT NT
R568Q NT
R504Q
IP3 2.14 41.7 35.6
(8.67  0.13) (7.38  0.07) (7.45  0.05)
0.9  0.1 0.7  0.1 0.8  0.1
IP2 641 974 1250
(6.19  0.09) (6.01  0.12) (5.90  0.11)
0.8  0.1 0.8  0.1 0.9  0.2
AdA 0.14 2.81 16.5
(9.85  0.04) (8.55  0.06) (7.78  0.06)
1.0  0.1 1.3  0.2 0.9  0.1
2’-dephospho-AdA 10.5 13.7 345
(7.98  0.07) (7.86  0.04) (6.46  0.08)
1.0  0.1 0.7  0.1 0.8  0.1
Ribophostin 1.92 ND 40.5
(8.72  0.18) (7.39  0.02)
0.9  0.2 0.9  0.1
Furanophostin 1.19 ND 52.5
(8.92  0.08) (7.29  0.03)
1.0  0.1 1.0  0.1
From equilibrium-competition binding assays, the Kd,p K d and Hill coefﬁcients (nHill) values for each ligand are shown for the NT and NT
mutants of IP3R1 measured in TEM. Parallel experiments with mutant NT fragments in CLM were not practicable because of the low afﬁnity
of the interactions. Results are means (Kd)o rm e a n s SEM (pKd and nHill) from 4–14 independent experiments.
AdA, adenophostin A; CLM, cytosol-like medium; IP2, inositol 4,5-bisphosphate; IP3, inositol 1,4,5-trisphosphate; IP3R, IP3 receptor; Kd,
equilibrium dissociation constant; ND, not determined; nHill, Hill coefﬁcient; NT, N-terminal; TEM, Tris/EDTA medium.
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Binding of IP3, AdA and their dephospho analogues to the NT, IBC and IBC mutants assayed in CLM
Kd (nM)
(pKd  SEM)
nHill  SEM
NT IBC IBC
R568Q IBC
R504Q
IP3 47.0 7.23 271 96.8
(7.33  0.16) (8.14  0.05) (6.57  0.04) (7.01  0.02)
0.8  0.2 1.0  0.1 1.6  0.3 1.3  0.2
IP2 3433 432 1077 624
(5.46  0.09) (6.37  0.04) (5.97  0.09) (6.21  0.06)
0.8  0.1 0.8  0.1 1.1  0.3 1.2  0.4
AdA 3.44 0.31 9.48 149
(8.46  0.11) (9.51  0.03) (8.02  0.09) (6.83  0.04)
1.3  0.2 1.3  0.3 1.3  0.6 1.5  0.2
2’-dephospho-AdA 77.2 8.82 26.4 308
(7.11  0.08) (8.05  0.12) (7.58  0.06) (6.51  0.08)
0.9  0.4 0.8  0.1 1.1  0.3 1.8  0.7
From equilibrium-competition binding assays, the Kd,p K d and Hill coefﬁcient (nHill) for each ligand are shown for the NT, IBC, IBCR568Q and
IBC
R504Q fragments of IP3R1 in CLM. Results are means (Kd)o rm e a n s SEM (pKd and nHill) from 3–6 independent experiments.
AdA, adenophostin A; CLM, cytosol-like medium; IBC, IP3-binding core; IP2, inositol 4,5-bisphosphate; IP3, inositol 1,4,5-trisphosphate; IP3R,
IP3 receptor; Kd, equilibrium dissociation constant; nHill, Hill coefﬁcient; NT, N-terminal.
Table 4
Functional responses of mutant IP3R1
IP3R1 IP3R1R568Q IP3R1R504Q
EC50 (mM) Release EC50 (mM) Release EC50 (mM)
Release (%)
(pEC50  SEM) (%) (pEC50  SEM) (%) (pEC50  SEM)
nHill  SEM nHill  SEM nHill  SEM
IP3 0.038 79  3 1.19 39  4 0.85 53  6
(7.42  0.02) (5.92  0.06) (6.07  0.04)
1.1  0.2 1.5  0.3 1.0  0.3
IP2 5.01 73  7 8.05 53  52 6 5 7  6
(5.30  0.08) (5.09  0.07) (4.58  0.14)
1.4  0.2 1.1  0.2 0.9  0.2
AdA 0.003 78  3 0.02 53  3 0.60 61  3
(8.51  0.05) (7.70  0.05) (6.219  0.002)
1.4  0.1 1.0  0.2 1.3  0.2
2’-dephospho-AdA 0.16 72  3 0.26 43  4 4.21 46  1
(6.80  0.02) (6.59  0.07) (5.38  0.05)
1.3  0.2 1.7  0.4 1.9  0.4
From experiments similar to those shown in Figures 2B, 3E and 4F, Ca
2+ release was measured in DT40 cells expressing only the indicated
mutant IP3R. Results show the pEC50, EC50, nHill and the maximal Ca
2+ release evoked by each agonist. Results are presented as means (EC50)
or means  SEM (pEC50, nHill and percentage Ca
2+ release) from 4–6 independent experiments, each with three determinations.
AdA, adenophostin A; IP2, inositol 4,5-bisphosphate; IP3, inositol 1,4,5-trisphosphate; IP3R, IP3 receptor; nHill, Hill coefﬁcient.
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chain (Figure 1A) (Bosanac et al., 2002). We mutated
R568 to Q and examined IP3 and AdA binding to the
mutant IBC, and Ca
2+ release via the mutant full-
length IP3R.
The afﬁnities of IP3 and AdA for the IBC were
similarly reduced (by 37-fold and 31-fold respec-
tively) by the R568Q mutation (DpKd = 1.57  0.07
for IP3, and 1.49  0.11 for AdA), whereas the afﬁni-
ties of IP2 and 2′-dephospho-AdA were minimally
affected (DpKd = 0.40  0.14 and 0.48  0.12 for IP2
and 2′-dephospho-AdA respectively) (Figure 3A and
B, Table 3, Table S2). Similar results were obtained
with NT
R568Q in TEM (Figure 3C, Table 2). These
Figure 3
R568 does not selectively enhance AdA binding. Equilibrium-competition binding to IBC
R568Q using
3H-IP3 (1.5 nM) and the indicated ligands in
CLM (A). Relative afﬁnities (Kd) of ligands for the IBCR568Q and IBC (B). Equilibrium-competition binding to the NTR568Q using 3H-IP3 (1.5 nM) and
the indicated ligands in TEM (C). Representative immunoblot (with anti-IP3R1 antibody, Ab1.5, top panel; and b-adaptin, bottom panel) for
DT40-KO cells (KO) and DT40 cells expressing IP3R1 or the indicated mutants (105 cells per lane). Molecular weight markers (kDa) are shown. The
blot is typical of six similar blots. IP3R expression (corrected for b-adaptin loading) is shown for each mutant relative to DT40-IP3R1 cells (%, means
 SEM) (D). Ca2+ release from permeabilized DT40-IP3R1R568Q cells evoked by the indicated ligands (E). Comparison of Ca2+ release for each ligand
in normal and mutant IP3R1
R568Q (F). Results are means  SEM, n  4. AdA, adenophostin A; CLM, cytosol-like medium; IBC, IP3-binding core; IP3,
inositol 1,4,5-trisphosphate; IP3R, IP3 receptor; Kd, equilibrium dissociation constant; NT, N-terminal; TEM, Tris/EDTA medium.
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1-phosphate of IP3 and the 2′-phosphate of AdA
similarly, and so lends further support to the view
that the latter at least partially mimics the
1-phosphate of IP3 (Figure 1B). But why, if IP3 and
AdA interact similarly with R568, should removal of
the 1-phosphate from IP3 increase its Kd more than
does removal of the 2′-phosphate from AdA
(Tables 1 and 2)? A likely explanation is that the
indirect interaction of the 1-phosphate of IP3 with
the backbone of K569 (Figure 1A) (Bosanac et al.,
2002) is stronger than the equivalent interaction
with the 2′-phosphate of AdA. Unfortunately,
mutagenesis using naturally occurring amino acids
cannot be used to dissect the role of this backbone
interaction. Introduction of a non-natural amino
acid, for example replacing K569 with an
a-hydroxyl acid residue to replace the backbone NH
with O, might address the question (Yang et al.,
2004). But the nonsense suppression techniques
required to insert the non-natural residue are not
presently available to us.
Functional assays of DT40 cells expressing
mutant IP3R do not allow absolute sensitivities to
agonists or the size of the agonist-sensitive Ca
2+ pool
to be precisely compared between cell lines because
it is impossible to establish stable cell lines with
identical levels of IP3R expression (Figure 3D). The
problem is less severe than might have been antici-
pated because even a substantial increase in IP3R
expression in DT40 cells (>20-fold) caused the sen-
sitivity to IP3 to increase by less than twofold (Dellis
et al., 2006). The mutations we have studied caused
much larger changes in IP3 sensitivity (~30-fold,
Table 4). Furthermore, levels of IP3R expression in
the stable DT40 cell lines expressing mutant IP3R
differed by no more than 3.5-fold from the line
expressing wild-type IP3R1 (Figure 3D).
In functional assays, using DT40 cells expressing
only IP3R1
R568Q,I P 3 and AdA were less potent than in
cells expressing wild-type IP3R1: the potencies of IP3
and AdA were reduced by 31-fold (DpEC50 = 1.50 
0.06) and sixfold (DpEC50 = 0.81  0.07) respectively.
By contrast, the potencies of IP2 and 2′-dephospho-
AdA were only very modestly reduced (1.6-fold,
DpEC50 = 0.21  0.11 for both ligands) (Figure 3E
and F, Table 4 and Table S3). The lesser Ca
2+ release
with maximally effective concentrations of all four
agonists in DT40-IP3R
R568Q cells (compare Figures 2B
and 3E) is probably attributable to the reduced level
of expression of IP3R in the mutant cell line
(Figure 3D). The selective effect of the R568Q muta-
tion on AdA and IP3, but not the dephospho ana-
logues, is consistent with our analyses of ligand
binding (Table 3). But the signiﬁcantly lesser effect
of the mutation on the functional responses to AdA
was unexpected because hitherto the interactions
between R568 have appeared similar for the
1-phosphate of IP3 and the 2′-phosphate of AdA.
These results suggest that disruption of the interac-
tion between R568 and the critical phosphates may
selectively reduce the efﬁcacy of IP3. That conclu-
sion would be consistent with evidence that inositol
2,4,5-trisphosphate is a partial agonist of IP3R
(Marchant et al., 1997b).
Selective interaction of AdA with R504
Our previous attempts to predict the binding mode
of AdA to the IBC using molecular docking sug-
gested that, in addition to possible interactions with
R568, the 2′-phosphate might also interact with the
amide NH of K569 and the side chain of R504
(Rosenberg et al., 2003). But our present results
(Figure 2) suggest that for AdA, the 2′-phosphate is
not a major determinant of its high afﬁnity. One of
the possible binding modes also suggested a cation-p
interaction between the adenine of AdA and the
guanidinium side chain of R504 (Rosenberg et al.,
2003) (Figure 4A). Many analyses of synthetic AdA
analogues lacking the adenine moiety suggest that
the adenine or another aromatic moiety is an
important determinant of the high-afﬁnity binding
of AdA. The AdA analogues lacking adenine, which
retain a phosphate group equivalent to the
2′-phosphate of AdA, typically have Kd values
similar to that for IP3 (Table 2) (Jenkins et al., 1997;
Tatani et al., 1998; Hotoda et al., 1999; Marwood
et al., 2000; Correa et al., 2001). R504 is one of
several residues to form a hydrogen bond with the
5-phosphate of IP3, via a bridging water molecule
(Bosanac et al., 2002), and probably also with the
equivalent 3″-phosphate of AdA (Rosenberg et al.,
2003) (Figure 1B). Mutation of R504 inhibits IP3
binding (Yoshikawa et al., 1996) and is likewise
expected to disrupt interaction of the 3″-phosphate
of AdA. But if the proposed cation-p interaction is
important for AdA binding, mutation of R504 might
additionally reduce AdA binding by disrupting
interactions with its adenine ring. The subsequent
experiments were designed to test this hypothesis.
As expected, because each ligand has a phos-
phate equivalent to the 5-phosphate of IP3, muta-
tion of R504 to Q signiﬁcantly reduced the afﬁnity
of both IP3 and AdA for the IBC (Figure 4B and C,
Table 3 and Table S3). However, whereas the afﬁnity
of IP3 was reduced by 13-fold (DpKd = 1.13  0.06),
the afﬁnity of AdA was reduced by 353-fold (DpKd =
2.55  0.05) (Figure 4B and C, Table 3 and Table S2).
Binding of the dephospho analogues was less
affected by the R504Q mutation: the decrease in
afﬁnity was 1.4-fold (pD=0.16  0.07) for IP2 and
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Similar results were obtained with NT
R504Q in TEM
(Figure 4D, Table 2).
A further prediction arising from our suggestion
that a cation-p interaction involving R504 and the
adenine moiety contributes to high-afﬁnity binding
of AdA is that adenophostin analogues lacking the
adenine moiety should be less affected by mutation
of R504. The results shown in Table 2 conﬁrm this
prediction for two such analogues, furanophostin
Figure 4
Selective interaction of AdA with R504. Model of AdA binding to the IBC highlighting a possible cation-p interaction between the adenine ring
of AdA and R504 of the IBC (Rosenberg et al., 2003) (A). Equilibrium-competition binding to IBCR504Q using 3H-IP3 (3 nM) and the indicated ligands
in CLM (B). Comparison of the binding of each ligand to normal and mutant IBC (C). Equilibrium-competition binding to NTR504Q using 3H-IP3
(1.5 nM) and the indicated ligands in TEM (D). Structure of the IBC (PDB 1N4K) highlighting the likely interactions of R504 with the phosphate
groups of IP3 (see text for further details). The red spheres represent water (E). Ca2+ release from permeabilized IP3R1R504Q cells evoked by the
indicated ligands (F). Comparison of Ca2+ release for each ligand via normal and mutant IP3R (G). Results (B–D and F–G) are means  SEM, n 
4. AdA, adenophostin A; CLM, cytosol-like medium; IBC, IP3-binding core; IP3, inositol 1,4,5-trisphosphate; IP3R, IP3 receptor; NT, N-terminal; TEM,
Tris/EDTA medium.
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reduced the afﬁnity of the NT for furanophostin by
44-fold (DpKd = 1.63  0.10) and for ribophostin by
21-fold (DpKd = 1.33  0.24).
Comparison of the effects of the R504Q mutation
on each pair of ligands (i.e. IP3 vs. AdA, and IP2 vs.
dephospho-AdA) indicates that for each there was a
25-fold greater decrease in the afﬁnity for the AdA
analogues (Figure 4C, Table 3 and Table S2). But the
lesser effects of the mutation on both dephospho
analogues is intriguing because R504 has not been
reported to interact with the 1-phosphate of IP3
(Bosanac et al., 2002). However, close inspection of
the crystal structure of the IP3-bound IBC also
reveals a possible indirect interaction, via water, of
R504 with the 1-phosphate (Figure 4E), although
this was not discussed in the original report
(Bosanac et al., 2002). It is not clear whether a
similar interaction could also exist for AdA, but the
possibility that both IP3 and AdA interact with R504
via their 1- and 2′-phosphates, respectively, is
appealing because it would explain the lesser effects
of the R504Q mutation on the dephospho ana-
logues (Figure 4C).
Functional analyses with DT40 cells expressing
IP3R1
R504Q conﬁrmed the results with binding. The
sensitivity of the mutant IP3R1
R504Q was signiﬁ-
cantly decreased for all ligands, although again the
effect on the dephospho analogues was more
modest than that on IP3 and AdA (Figure 4F and G,
Table 4 and Table S3). Most importantly, whereas
the EC50 for IP3 was reduced by 23-fold (DpEC50 =
1.35  0.17), that for AdA was reduced by 196-fold
(DpEC50 = 2.29  0.06). These DpEC50 values for IP3
and AdA are signiﬁcantly different. Together, the
binding and functional analyses establish that
R504 is more important for binding of AdA than
for IP3. The selective effect of R504 on AdA binding
does not result from interaction with the
2′-phosphate of AdA, but is instead likely to reﬂect
the contribution of a cation-p interaction between
the adenine of AdA and the guanidinium side
chain of R504 (Figure 4A).
Discussion
Inositol 1,4,5-trisphosphate and AdA are full ago-
nists of IP3R (Rossi et al., 2009), but the latter binds
with substantially greater afﬁnity than does IP3
(Takahashi et al., 1994b; Correa et al., 2001)
(Figure 2F). We have established that the IBC, to
which IP3 binds to initiate activation of the IP3R, is
alone capable of binding AdA with ~20-fold greater
afﬁnity than IP3 (Table 3). Presently available evi-
dence suggests that once AdA or IP3 has bound
to the IBC, each causes indistinguishable activa-
tion of the IP3R (Rossi et al., 2009). The increased
potency of AdA, relative to IP3, in evoking Ca
2+
release via IP3R is therefore likely to be entirely
attributable to the stronger interactions between
AdA and the IBC. This conclusion provided the
impetus for resolving the interactions between
AdA and the IBC that mediate its high-afﬁnity
binding.
The 4″- and 3″-phosphates of AdA mimic the
essential 4,5-bisphosphate moiety of IP3 (Figure 1B)
and the 2′-phosphate of AdA has been thought to
at least partially mimic the 1-phosphate of IP3
(Takahashi et al., 1994b). None of our present
results challenges this interpretation. Hitherto, an
appealing explanation for the high afﬁnity of AdA
has been the suggestion that its 2′-phosphate is
better placed than the 1-phosphate of IP3 to inter-
act with residues in the IBC (Takahashi et al.,
1994c; Wilcox et al., 1995). Our results establish
that this is not the basis of the high-afﬁnity
binding of AdA. First, removal of the 2′-phosphate
Figure 5
Differential interactions of IP3 and AdA with the IBC. Interactions of the phosphate groups of IP3 with the residues mutated in this study are
highlighted (Bosanac et al., 2002). Predicted interactions of the phosphate groups of AdA with the same residues, and the proposed cation-p
interaction between the adenine moiety and R504 are shown. AdA, adenophostin A; IBC, IP3-binding core; IP3, inositol 1,4,5-trisphosphate.
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vity than does removal of the 1-phosphate from
IP3 (Figure 2G, Tables 1–3 and Table S1). Second,
mutation of R568, one of the key residues with
which the 1-phosphate of IP3 interacts (Bosanac
et al., 2002), similarly reduces the afﬁnity of the
IP3R for IP3 and AdA, while minimally affecting
binding of IP2 or 2′-dephospho-AdA (Figure 3A and
B, Table 3 and Table S1). These results establish
that the 2′-phosphate of AdA partially mimics
the 1-phosphate of IP3, but the latter probably
interacts more strongly with the backbone of
K569. We conclude that the high afﬁnity of AdA
for IP3R does not result from its 2′-phosphate
behaving as a supra-optimally positioned mimic of
the 1-phosphate of IP3 (Figure 5).
Considerable evidence suggests that the adenine
group of AdA contributes signiﬁcantly to its high-
afﬁnity binding (Tatani et al., 1998; Hotoda et al.,
1999; Marwood et al., 2000; Correa et al., 2001;
Rosenberg et al., 2003) and our molecular model-
ling has suggested that this might result from a
cation-p interaction between the adenine and the
guanidinium side chain of R504 (Rosenberg et al.,
2003) (Figure 4A). Our present results are consistent
with this suggestion. Because R504 interacts with
the 5-phosphate of IP3 (Figure 1A) and, almost cer-
tainly, in similar fashion with the equivalent
3″-phosphate of AdA (Figures 1B and 5), mutation
of this residue (R504Q) signiﬁcantly decreased the
afﬁnity of the IP3R for both ligands. But more
importantly, the effects, in both functional and
binding assays, were signiﬁcantly greater for AdA
than for IP3 (Figure 4D and G, Tables 2–4, Tables S2
and S3). These results establish the greater impor-
tance of R504 for AdA binding, which would be
consistent with AdA, but not IP3, forming a
cation-p interaction with this residue (Figure 5). We
conclude that the high afﬁnity of AdA for IP3Ri s
not due to its 2′-phosphate, and that AdA interacts
more strongly than IP3 with R504, most likely
reﬂecting a cation-p interaction between the
adenine group and R504. This interaction may
provide opportunities for synthesis of less polar
ligands of IP3R (Sureshan et al., 2009).
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Table S1 Relative potencies and afﬁnities of IP3 and
AdA analogues interacting with native IP3R1 and its
N-terminal fragments. The table shows the relative
effectiveness for each pair of ligands in evoking Ca
2+
release from DT40-IP3R1 cells (DpEC50) and in
binding (in TEM) to full-length IP3R1 and NT, and
binding (in CLM) to the NT or IBC (DpKd). Results
are shown as means  SEM, from at least three
independent experiments. The data from which
these values are derived are shown in Figure 2.
Table S2 Relative afﬁnities of IP3 and AdA ana-
logues interacting with wild-type and mutant IBC.
For each ligand, the relative afﬁnity (DpKd) is shown
for mutant and wild-type IBC (in CLM). Results
are shown as means  SEM, from at least three
independent experiments. The data from which
these values are derived are shown in Figures 2, 3
and 4.
Table S3 Relative potencies of IP3 and AdA ana-
logues interacting with mutant IP3R1. For each
ligand the relative potency in evoking Ca
2+ release
(DpEC50) is shown for wild-type and mutant IP3R.
Results are shown as means  SEM, from at least
three independent experiments. The data from
which these values are derived are shown in Fig-
ures 2, 3 and 4.
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